Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-06-28 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE
Foreign Filer Report
2021-06-28 English
Forxiga recommended in EU for patients with CKD
Regulatory Filings Classification · 95% confidence The document is a press release issued on June 28, 2021, identified by the 'RNS Number' header and the closing statement referencing 'RNS, the news service of the London Stock Exchange'. The content announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the EU approval of the drug Forxiga for Chronic Kidney Disease (CKD). This is a specific corporate announcement regarding regulatory/clinical progress, not a comprehensive annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS). Since it is a specific announcement about a regulatory milestone (CHMP recommendation), it fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory update, or potentially a general announcement. Given the options, RNS serves as the best fit for a general regulatory news service announcement that isn't a core financial report or a specific insider/dividend event. However, since it is a formal announcement of a significant regulatory event (drug approval recommendation), and RNS is defined as the fallback for miscellaneous filings, I will classify it as RNS, as it is distributed via the RNS system.
2021-06-28 English
Nirsevimab PhII/III trial confirms safety profile
Regulatory Filings Classification · 98% confidence The document begins with an RNS Number (2366D) and a date (28 June 2021), indicating it is a regulatory announcement. The content discusses clinical trial results (MEDLEY Phase II/III) for a drug (Nirsevimab) and mentions future regulatory submissions ('We look forward to sharing the results with regulators'). It is a press release format providing updates on R&D and commercial activities, which is typical for a general regulatory announcement that isn't a specific financial report (like 10-K or IR) or a dedicated earnings release (ER). Since it is a formal, time-sensitive announcement disseminated via the Regulatory News Service (RNS) system, and it doesn't fit the specific definitions for financial reports, management changes, or shareholder votes, the most appropriate classification is the general regulatory filing category.
2021-06-28 English
LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCER
Foreign Filer Report
2021-06-24 English
Lynparza approved in China for prostate cancer
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated '24 June 2021'. It announces a specific corporate event: the conditional approval of Lynparza in China for prostate cancer treatment. The text concludes with standard boilerplate language referencing RNS, the London Stock Exchange, and the Financial Conduct Authority, and ends with 'END'. This structure is characteristic of a regulatory news service announcement, which is a general category for official, timely disclosures that don't fit into more specific financial report types (like 10-K, ER, or IR). Since it is a specific announcement of regulatory/market-moving news distributed via RNS, the most appropriate classification is Regulatory Filings (RNS). It is not a full report (10-K, IR), an earnings release (ER), or a management discussion (MDA).
2021-06-24 English
ORPATHYS APPROVED IN CHINA FOR LUNG CANCER
Foreign Filer Report
2021-06-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.